Biomarkers and Biotypes to Predict Early Psychosis Outcomes in Bipolar Disorder and Related Conditions
Official title: 5/5 - Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
Funded at University of Georgia · NIH-11412635 · Data updated 2026-11-12
Aiming to use brain and cognitive biomarkers to predict how young people with early psychosis will fare over the first year of care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project start | August 15, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $151,000 |
| NIH project number | 5R01MH127172-05 |
| Project ID | NIH-11412635 on NIH RePORTER |
Who could benefit from this research
✓Could help
Young adults (approximately 18–35) with early psychosis enrolled in coordinated specialty care clinics.
✕Less likely to help
Patients outside the early psychosis window or not engaged in CSC services may not benefit.
What this research studies
This project follows young adults with early course psychosis in coordinated specialty care clinics to see how biomarkers (like EEG and eye tracking) plus clinical data can forecast outcomes over 1, 6, and 12 months. Researchers will categorize patients into Biotypes and compare these groups with how well they recover or decline, guiding personalized treatment planning. Data from multiple sites will be combined to understand trajectories and tailor interventions to individual needs. The study builds on prior BSNIP work showing that biomarker-based groups can reflect illness course across bipolar and schizophrenia-related conditions.
Why it matters
Potential benefit: If successful, clinicians could tailor treatment intensity and duration based on biomarker profiles to improve recovery and functioning.
How similar studies have gone: Previous BSNIP work has shown biomarker-based subgroups correlate with illness trajectories in psychosis.
Where this research is happening
-
University of Georgia
Athens, United States Active
Researchers
- Principal investigator: Clementz, Brett a — University of Georgia
- Study coordinator: Clementz, Brett a
Related research
Other NIH-funded projects on the same topics.
-
Psychosis in diverse settings across the world
This project studies how psychotic disorders show up and respond to treatment in adults with diverse backgrounds, including populations in Africa, the Caribbean, and other Global South settings.
-
Psychosis in Diverse Settings: Understanding Symptoms and Treatment Across Global South
A human-facing study will look at how psychotic disorders present and respond to treatment in adults from Africa, the Caribbean, and other Global South settings, using genetic and clinical data.
-
A new online brain-scan-style tool to spot early psychosis risk
A new online-based set of tasks and a computer model aims to identify people at high risk for developing psychosis earlier and more accurately.
-
Genetic clues for early-onset psychosis in Latino youth
This project looks at the genes of young people with early-onset psychosis and compares them with similar youths without psychosis to find genetic factors that contribute to the illness.
-
Biomarkers to tailor rehab for Veterans with schizophrenia
A clinician-scientist is developing a brain-based biomarker to guide personalized rehabilitation for Veterans with schizophrenia.
-
Computational analysis of facial expression in early psychosis
Aims to develop computer-based measures of facial expression in people at risk for or with schizophrenia to help track symptoms and guide future trials.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.